Patients admitted to an Intensive Care Unit (ICU) frequently have underlying cardiac dysfunction. Early interventions are sometimes difficult to initiate because of diagnostic uncertainty as to whether cardiac failure is present As B-type natriuretic peptide (BNP) has been shown to be increased in cardiac dysfunction, we sought to demonstrate whether BNP can be used as a screening tool for cardiac dysfunction in patients admitted to ICU.
Brain natriuretic peptide (BNP), a 32-amino acid polypeptide, was first isolated in 1988 from porcine brain 1 . It shares similar physiological actions to that of atrial natriuretic peptide (ANP), including vasodilation and inhibition of the renin-angiotensinaldosterone axis 2, 3 . While ANP is released from the atria in response to atrial stretch 4 , BNP is principally synthesized in, and secreted from, the ventricles 5 in response to volume expansion and pressure 6, 7 . Since BNP has been shown to be elevated in patients with left ventricular (LV) dysfunction 8 , a number of studies have proposed the utilization of BNP as a diagnostic tool for congestive heart failure 9,10,11 and for dyspnea 12 .
Cardiac dysfunction is commonly found in patients admitted to the ICU, but it is not always appreciated if heart disease is not the primary pathological process 13 . Early detection of the presence of cardiac disease will often lead to a very different course of patient management in ICU. Such early interventions have been shown to improve survival and increase well-being 14, 15 . Appropriate intervention may be delayed unless evaluation by echocardiography is part of the routine screening process. Although echocardiography is an invaluable tool for the diagnosis of cardiac dysfunction, it is still not readily available in many ICU settings. Even when echocardiography is available, the cost of the machine, availability of sonographers and the feasibility of performing a study in every admission make it impractical to use as a screening tool for cardiac disease at the admission point. Therefore, there is a need for a useful, simple, fast and affordable screening tool in the intensive care setting. By employing a rapid immunofluorescence assay system for BNP, we sought to determine if BNP levels could serve as a screening tool for cardiac decompensation in patients admitted to ICU.
METHOD
All patients admitted to the general ICU of a tertiary referral hospital during a study period of four weeks were included in the study. The patient characteristics were listed in Table 1 . A total of 84 routine admission blood samples from 84 patients admitted over the study period were analysed for BNP. BNP levels were measured using the Triage BNP test kit (Biosite Diagnostics Inc; San Diego, California) according to the manufacturer's instruction 16 . Four millilitres of blood were collected into a K-EDTA vial. An aliquot of 200 µl of blood was applied to the reservoir of the BNP panel (Biosite Diagnostics Inc) using the provided pipette. The panel was allowed to stand at room temperature for 20 minutes to allow the blood to flow into the immunofluorescent reaction chamber by capillary action. The panel was then inserted into the Triage BNP fluorimeter for measurement of BNP level. All samples were measured within four hours of blood collection. The senior intensivists were blinded from the BNP measurements while making their diagnoses as to whether or not the patients had cardiac dysfunction.
Cardiac dysfunction in this study was defined as the presence of one or more of the following conditions: LV systolic dysfunction, LV diastolic dysfunction, right ventricular (RV) systolic dysfunction or haemodynamically overloaded RV. The diagnoses were based on past history, symptoms, ECG, chest X-ray, echocardiography, blood tests and physical examination. Echocardiography were performed on all patients except those whose images were impossible to obtain and those who had low risk of having cardiac disease, such as young patients with isolated head injury. Once the diagnosis was made, the patient was placed in one of the following two groups: (1) cardiac patients: patients admitted due to a cardiac cause, or due to other causes but diagnosed with cardiac dysfunction; (2) non-cardiac patients: patients without any cardiac dysfunction.
This study was approved by the Wentworth Area Health Services Ethics Committee and informed consent was obtained either from the patients or from their next-of-kin.
Echocardiography
Echocardiography was carried out using the ATL HD5000 (Bothell, WA) ultrasound machine 17 . LV systolic function was based on LV ejection fraction measured using the Simpson's method 18 . LV systolic dysfunction was defined as LVEF <50%. LV diastolic function was concluded from the mitral inflow parameters (E/A ratio, E-deceleration time and isovolumic relaxation time), pulmonary venous flow parameters (systolic:diastolic flow ratio, atrialreversal velocity), mitral valve (MV) annulus tissue-Doppler imaging (E'/A') as well as the mitral E-flow propagation velocity.
LV diastolic dysfunction was regarded as positive when all or most of the diastolic parameters were consistent with one of the three stages of diastolic dysfunction: impaired relaxation, pseudonormal pattern and restrictive pattern. RV systolic function was inferred from the tricuspid valve annulus displacement using M-mode with the cursor placed at the lateral aspect of the RV in the apical 4 chamber view. RV systolic dysfunction was defined when the total peak-to-peak displacement of the tricuspid valve annulus was <2.15 cm 19 .
Haemodynamic states (i.e. volume or pressure overload) of the RV were determined from RV size, the presence of paradoxical interventricular septal motion (during systole or diastole) as well as the RV peak systolic pressure (RVSP). RVSP was determined using the equation RVSP=4TR 2 +RAP, where TR is the peak tricuspid regurgitation velocity and RAP is the right atrial pressure. RAP was estimated from the diameter of the inferior vena cava and the change in diameter during inspiration/expiration. If a central line was present, the RAP was replaced by the central venous pressure. If a pulmonary artery (PA) catheter was present, RVSP was determined from the PA systolic pressure.
Statistics
The detectable range of BNP level is 0 to 1300 pg/ml. Readings over 1300 pg/ml were taken as 1300 pg/ml. The results were expressed as mean±SD in the text. Class comparisons were made primarily using the nonparametric Wilcoxon Rank-Sum test due to the skewness (positive) of BNP distribution. Where significant number of ties were present in the data sets, Kolmogorov-Smirnov test was used to reaffirm the significance. In appropriate cases, the significance was also confirmed using Student t-test after log-transformation of BNP values. For comparisons that were significant using the t-test, the powers achieved were over 90% at an α of 0.01. Correlation between BNP level and age were achieved using linear regression. Univariate and multivariate logistic regressions were performed using the presence of cardiac dysfunction as the response variable, and BNP and age as the predictor variables. A confidence level of P<0.05 was taken as significant. A receiver-operating characteristic curve (ROC) was constructed using a statistical package (NCSS-PASS, Kaysville, Utah). The presence or absence of cardiac dysfunction was used as the response variable and the BNP levels were use as the criterion variable. The range of the criterion variable was divided into twenty equal intervals and a two-bytwo table was calculated for each interval to find out the sensitivity and specificity. Each interval ended with a cut-off point.
RESULTS

BNP level in ICU patients
The blood BNP levels for a total of 84 patients were measured at the admission point. The mean BNP level was 205±306 pg/ml (range: 0-1300 pg/ml; n=84). Among the 26 patients admitted under Group 1, three patients were admitted due to cardiac failure or following a cardiac arrest and 23 were admitted due to other causes but diagnosed with cardiac dysfunction. The types of cardiac dysfunction diagnosed are listed in Table 1 . Three patients in Group 1 had BNP levels >1300 pg/ml, the remainder of the group exhibited BNP levels ranging from 107 to 1030 pg/ml. The mean level of BNP in Group 1 was 516± 385 pg/ml (n=26). The non-cardiac compromised patients (Group 2) exhibited a mean BNP level of 67 ±89 pg/ml (n=58) which was significantly lower than that of Group 1 (P<0.0001).
Age and BNP level
The average age of the patients was 60.9±18.9 years, ranging from 17 to 86 years. The mean age for Group 1 was 72.7±11.2 y and was significantly higher than that of Group 2 (54.3±18.9 y; P<0.005). A correlation between BNP level and age was found to be negatively skewed ( Figure 1A) . A plot of ln(BNP) v age 2 yielded a significant positive relationship (slope =0.0004, R 2 =0.27; P<0.0001) ( Figure 1B ).
If the analysis was restricted to patients with age ≥55 y, the mean age between the two groups (I: 74.0 ±9.2 y, n=25; II: 70.0±9.8 y, n=28) became similar (P>0.05). The significant correlation between BNP and age no longer existed (slope=0.0003, R 2 =0.06; P>0.1) ( Figures 1C-1D ). However, the BNP level in Group 1 (≥55y) was 531±384 pg/ml (n=25) and remained significantly higher than Group 2 (≥55 y) (89±102 pg/ml, n=28; P<0.001).
ROC curve for BNP
An ROC curve showing the sensitivity and specificity of BNP in discriminating patients with clinically significant cardiac dysfunction from those free from clinical cardiac dysfunction is shown in Figure 2 . The area under the curve (accuracy) is 0.96. Table 2 shows the sensitivity, specificity, positive and negative predictive values of selected BNP levels. A BNP cut-off value at 144 pg/ml exhibited a 92% sensitivity, 86% specificity and 97% negative predictive value. A cut-off value at 193 pg/ml showed a 81% sensitivity and 93% specificity, and the negative predictive value was 92%. Values at and above 241 pg/ml had a sensitivity of only 69% or less. If the analysis was limited to patients ≥55 years, the sensitivity improved slightly to 96% and 84% at cut-off of 144 pg/ml and 193 pg/ml, respectively ( Table 2) .
Predictor for the presence of cardiac disease
The results of the univariate analysis model using BNP (≥144 pg/ml) and age (≥55 y) as the predictor variables showed that BNP and age alone were significant predictors for cardiac dysfunction ( Table 3 ). The results of the multivariate analysis was also included in Table 2 , which showed that the most significant predictor for the presence of clinical cardiac 23 dysfunction was BNP level ≥144 pg/ml. Although age (≥55 y) was a significant predictor by itself, it became insignificant in the multivariate model.
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DISCUSSION
The present study showed that nearly one third of the patients admitted to ICU were identified to have some form of cardiac pathology. A positive diagnosis for cardiac dysfunction was closely related to an increased BNP level. We found that a BNP level of ≥144 pg/ml was strongly associated with the presence of cardiac dysfunction. A number of biochemical markers are available for screening or diagnosis of cardiac insult, including troponin I 20 and creatine kinase-MB 21 . However, these markers are not general cardiac markers but are more specific for myocardial ischemia or infarction 22 . To fulfil the function as a screening tool for cardiac disease, the marker should ideally be able to underscore the presence of a wide spectrum of cardiac conditions including systolic or diastolic dysfunction or both. Recently, the use of BNP as a diagnostic and screening tool for left ventricular dysfunction has received wide attention [8] [9] [10] [11] . Amongst them, two studies have shown that BNP is useful for establishing or excluding congestive heart failure in patients with acute dyspnea in emergency settings 9, 11 . Not only does BNP have a high sensitivity and specificity for left ventricular systolic dysfunction 23 , it is also an independent predictor of elevated left ventricular end-diastolic pressure 8 . In a recent study, Lubien et al has confirmed earlier studies that BNP can reliably detect the presence of diastolic dysfunction 24, 25 . BNP has also been shown to correlate with the NYHA classification 26 . Although an elevated BNP level is well established to be related to left ventricular stress, a number of studies also reported that the BNP mRNA level in the right ventricle was also increased in response to volume or pressure stress 27, 28 . Previous study has also shown that an elevated BNP level is associated with increased mortality rates in patients with pulmonary hypertension 29 . In view of these findings, we have grouped LV dysfunction patients with those who had a haemodynamically overloaded RV into Group I in this study. We have found that not only had BNP level increased in patients with LV dysfunction but also in those with RV dysfunction or hemodynamically stressed RV.
Age has been found to bear a positive relationship with BNP levels in this study and also in other studies 22 . Given that the prevalence of CHF and LV systolic dysfunction increase with age 30 and that BNP is related to LV dysfunction, it is not surprising to observe such a relationship in this study. This phenomenon was partly reflected in the negatively skewed BNP vs age relationship. When the analysis was restricted to patients with age 55 or over, the correlation between age and BNP weakened and became insignificant. However, the significant difference of BNP levels between the two groups (Group 1 and 2) remained, suggesting strongly that BNP was related to the presence of cardiac dysfunction. This contention was supported from the multivariate logistic regression analysis which showed that among BNP and age, BNP was the only significant and strong predictor for cardiac dysfunction.
ROC with similar accuracies (area under the curve) were reported in a number of studies [9] [10] [11] 16, [23] [24] [25] . When all admissions were taken into consideration in the present study, a sensitivity of 92% and a negative predictive value of 97% were found for BNP of 144 pg/ml. At a cut-off point of 193 pg/ml, the sensitivity and negative predictive values were 81% and 92% respectively. When the analysis were restricted to patient age ≥55, the sensitivity reached 96% at a cut-off of 144 pg/ml. With the purpose of utilizing BNP as a screening tool, we recommend a cut-off point of 144 pg/ml to be used in critically ill patients due to its higher sensitivity and negative predictive value. The higher sensitivity would allow clinicians to include probable cardiac patients, whilst the high negative predictive value would help rule out patients that are unlikely to have any clinical significant cardiac dysfunction. This cut-off point applies equally well when the analysis is limited to patient ≥55 years. 25 Both the univariate and multivariate analysis confirms that BNP at a cut-off at 144 pg/ml serves as a strong predictor for cardiac disease. A similar cut-off value of 100 pg/ml is recommended by the manufacturer and by Maisel et al 11 . However, one should bear in mind that the cardiac patients in this study comprised a variety of cardiac diseases whereas other studies only included patients with a single type of cardiac pathology. Direct comparison of cut-off points with those studies may not be cogent.
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In this study, we did not investigate the superiority of BNP to other investigative methods in the diagnosis of cardiac dysfunction. For example, comparison with echocardiography was not made, because it was one of the investigations on which the physicians' diagnoses were based. Also, we not have related BNP levels to different types of cardiac disease found because of the frequent presentation of more than one cardiac problem in a single patient. For instance, some patients had both left ventricular systolic and diastolic dysfunction, whilst some experienced both left and right ventricular systolic dysfunction. As it is anticipated that BNP will be used as a screening tool and the evaluation of cardiac disease will rely on other investigative methods, we do not recommend using BNP alone in differentiating cardiac diseases. In fact, it is impracticable to utilize BNP for such a purpose. To illustrate, the BNP levels for patients with left ventricular systolic or diastolic dysfunction were found to lie in the same range and it was impossible to differentiate left ventricular systolic dysfunction from diastolic dysfunction without performing echocardiography 10, 23, 24 .
To the best of our knowledge, this the first study to show that BNP can be used as a screening device for clinically important cardiac dysfunction in the ICU. The present study showed that an increase in BNP level is enough to warrant further cardiac investigations. Given that cardiac investigations are often expensive, a prior screening of BNP would limit the number of patients undergoing these investigations. In this context, it is noteworthy that a BNP blood test costs about 20 to 25% of a standard transthoracic echocardiography in Australia. As the hospital cost per patient is the highest for ICU patients, earlier interventions for cardiac dysfunction in these patients may provide an opportunity for saving costs by way of improved care and earlier discharge. In Australia, there are growing number of hospitals providing facilities for measuring BNP or N-terminal BNP (NT-BNP) level and the introduction of this measurement as part of a routine screening test during ICU admission is anticipated in the future.
